All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
#SOHO2024: Chronic lymphocytic leukemia and small lymphocytic lymphoma
To update you on the exciting content presented at the Society of Hematologic Oncology (SOHO) 2024 Annual Meeting, we have collated our social media coverage. Catch up with our live social media coverage relating to chronic lymphocytic leukemia and small lymphocytic leukemia below.
CONGRESS | #SOHO2024@Othman_Al_Sawaf, @UKKoeln, discusses clinical implications of using MRD as a surrogate for PFS or OS. While MRD showed moderate-to-weak correlation with OS and strong correlation with PFS on a trial level, he suggests that MRD shouldn’t be used as a primary… pic.twitter.com/gg6QFY602w
— Lymphoma Hub (@lymphomahub) September 10, 2024
CONGRESS | #SOHO2024
— Lymphoma Hub (@lymphomahub) September 9, 2024
Lydia Scarfò, @SanRaffaeleMI, presents an overview of covalent BTKi. Next generation cBTKis, acalabrutinib and zanabrutinib, have improved tolerability profile compared with ibrutinib. In the GIMEMA CLL2121 study in >1200 patients with CLL, 12-m OS was 82.9%… pic.twitter.com/Aerw0HTElA
CONGRESS | #SOHO2024 | POSTER
— Lymphoma Hub (@lymphomahub) September 9, 2024
William G. Wierda @MDAndersonNews presents exploratory analyses from the TRANSCEND CLL 004 trial of liso-cel in pts with R/R CLL/SLL. Baseline characteristics such as low tumor burden & fewer lines of prior systemic therapies were associated with… pic.twitter.com/NQxZiKqLeJ
CONGRESS | #SOHO2024 | POSTER
— Lymphoma Hub (@lymphomahub) September 9, 2024
William G. Wierda @MDAndersonNews shared results of the BRUIN 1/2 trial of pirtobrutinib in R/R CLL/SLL. N=35, 24 mo PFS was 74.7% & 81.8% (IRC & INV assessed, resp); ORR was 91.4% & 94.3% (IRC & INV assessed, resp). Safety profile was similar to… pic.twitter.com/4NrWqOCnwh
CONGRESS | #SOHO2024 | POSTER
— Lymphoma Hub (@lymphomahub) September 9, 2024
Arnon P. Kater @amsterdamumc shared early results of the EPCORE CLL-1 trial of epcortitamab in Richter's transformation (RT). N=38, mFU=12.9 mo, ORR was 53% (60% & 44% in 1L RT & 2L RT, resp), CR rate was 42% (50% & 33% in 1L RT & 2L RT, resp), mOS… pic.twitter.com/MVm3YxZK3D
CONGRESS |#SOHO2024 | POSTER
— Lymphoma Hub (@lymphomahub) September 9, 2024
Santiago Ossorio Prendes at Hospital Universitario Gregorio Marañon, reports 6-year time to next treatment extrapolation curve from the GLOW trial of first-line ibrutinib + venetoclax in elderly/unfit pts with CLL. Projected proportion of patients… pic.twitter.com/XCFoHBt89A
CONGRESS | #SOHO2024
— Lymphoma Hub (@lymphomahub) September 6, 2024
William Wierda, @MDAndersonNews, discusses whether continuous therapy is the best option for high-risk pts with CLL. In pts with del(17p)/TP53 mutations, second generation covalent BTK inhibitors (such as ibrutinib) show median PFS of 6+ years, however, are… pic.twitter.com/vAmatBsYuy
CONGRESS | #SOHO2024
— Lymphoma Hub (@lymphomahub) September 6, 2024
William Wierda, @MDAndersonNews, presents post hoc exploratory analysis results of the phase I/II TRANSCEND CLL 004 study evaluating characteristics associated with response to liso-cel in pts with R/R CLL/SLL (n=87). OR and CR rates did not correlate with… pic.twitter.com/iOwOwwnxA3
CONGRESS | #SOHO24 | POSTER
— Lymphoma Hub (@lymphomahub) September 5, 2024
Jan Burger @MDAndersonNews reports 10-year analysis from RESONATE-2 study. 1L ibrutinib continues to show survival benefit in older adults with CLL/SLL including those with the high risk genomic clinical features. 9 yr PFS & OS were 49.7% & 68.0%; No… pic.twitter.com/C1e6RiBMe6
CONGRESS | #SOHO24 | POSTER
— Lymphoma Hub (@lymphomahub) September 5, 2024
William Wierda @wwierda @MDAndersonNews presented 5.5 yr follow up of the phase II CAPTIVATE study. Fixed-duration ibrutinib+venetoclax treatment shows meaningful benefit in pts with CLL/SLL and high-risk genomic features (del(17p)/mutated TP53,… pic.twitter.com/BLKQz5KAxa
CONGRESS | POSTER | #SOHO2024 |
— Lymphoma Hub (@lymphomahub) September 4, 2024
Tamar Tadmor @TadmorTamar presents the phase III BELLWAVE-011 study which will investigate nemtabrutinib vs ibrutinib or acalabrutinib in pts with treatment-naïve CLL/SLL (N=1,200). Primary objectives are to evaluate ORR and PFS, with secondary… pic.twitter.com/eTapscE0Xf
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content